Congress trades and big insider sales, sent the day they're filed. Free.
Open in TelegramOfficers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.
Kurtz George0B / 217S · 10 late217 trades$54.77M
DRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
MTDRMatador Resources CoNov 5 – Nov 98 insiders$625K
FERGFerguson Enterprises Inc. /DE/Oct 12 – Oct 167 insiders$7.38M
SYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M
UPBDUPBOUND GROUP, INC.Nov 2 – Nov 37 insiders$1.34M
IBEXIBEX LtdSep 14 – Sep 166 insiders$2.01M
ARQQArqit Quantum Inc.Oct 2 – Oct 136 insiders$369K
BBTBeacon Financial CorpOct 26 – Oct 306 insiders$274K| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 36 | Garg PushkalEVP Chief R&D |  ALNYALNYLAM PHARMACEUTICALS, INC.Open-market sale | SELL | $15K 41 sh | Jan 14, 2026 |
| 36 | McBee BranninChief Development Officer | CRWVCoreWeave, Inc. Open-market sale · 10b5-1 plan | SELL | $467K 5,181 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 36 | Tanguler TolgaEVP, Chief Commercial Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $7,047 19 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 36 | Tanguler TolgaEVP, Chief Commercial Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $44K 123 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 36 | Garg PushkalEVP Chief R&D | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $31K 85 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 36 | Poulton Jeffrey V.EVP, Chief Financial Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $10K 27 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 36 | Garg PushkalEVP Chief R&D | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $34K 92 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 36 | Poulton Jeffrey V.EVP, Chief Financial Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $13K 36 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 36 | Garg PushkalEVP Chief R&D | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $6,676 18 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 36 | Tanguler TolgaEVP, Chief Commercial Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $5,667 15 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 36 | Garg PushkalEVP Chief R&D | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $17K 47 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 36 | Garg PushkalEVP Chief R&D | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $34K 96 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 36 | Garg PushkalEVP Chief R&D | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $7,137 19 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 36 | Garg PushkalEVP Chief R&D | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $5,242 14 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 36 | Poulton Jeffrey V.EVP, Chief Financial Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $27K 73 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 36 | Tanguler TolgaEVP, Chief Commercial Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $26K 73 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 36 | McBee BranninChief Development Officer | CRWVCoreWeave, Inc. Open-market sale · 10b5-1 plan | SELL | $387K 4,240 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 35 | Greenstreet YvonneDirector, Chief Executive Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $459K 1,259 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 35 | Greenstreet YvonneDirector, Chief Executive Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $353K 980 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 35 | Greenstreet YvonneDirector, Chief Executive Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $279K 778 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 35 | Armenta AnthonyChief Software & Data Officer |  SERVServe Robotics Inc. /DE/Open-market sale | SELL | $56K 3,893 sh | Jan 14, 2026 traded Jan 13, 2026 |
| 35 | Greenstreet YvonneDirector, Chief Executive Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $510K 1,395 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 35 | Frank MalcolmDirector |  FDSFACTSET RESEARCH SYSTEMS INCOpen-market sale | SELL | $308K 1,045 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 33 | Soule Randy10% Owner |  SAFXXCF Global, Inc.Open-market sale | SELL | $31K 200.0K sh | Jan 14, 2026 traded Jan 9, 2026 |
| 33 | McBee BranninChief Development Officer | CRWVCoreWeave, Inc. Open-market sale · 10b5-1 plan | SELL | $129K 1,414 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 33 | McBee BranninChief Development Officer | CRWVCoreWeave, Inc. Open-market sale · 10b5-1 plan | SELL | $62K 693 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 33 | Soule Randy10% Owner | SAFXXCF Global, Inc. Open-market sale | SELL | $32K 200.0K sh | Jan 14, 2026 traded Jan 9, 2026 |
| 33 | Soule Randy10% Owner | SAFXXCF Global, Inc. Open-market sale | SELL | $32K 200.0K sh | Jan 14, 2026 traded Jan 9, 2026 |
| 33 | Lo FrancisChief People Officer | ADPTAdaptive Biotechnologies Corp Open-market sale · 10b5-1 plan | SELL | $1.41M 79.6K sh | Jan 14, 2026 traded Jan 12, 2026 |
| 33 | McBee BranninChief Development Officer | CRWVCoreWeave, Inc. Open-market sale · 10b5-1 plan | SELL | $156K 1,727 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 32 | Greenstreet YvonneDirector, Chief Executive Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $94K 263 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 32 | Greenstreet YvonneDirector, Chief Executive Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $87K 247 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 32 | Greenstreet YvonneDirector, Chief Executive Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $96K 269 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 32 | Greenstreet YvonneDirector, Chief Executive Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $109K 301 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 32 | Greenstreet YvonneDirector, Chief Executive Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $226K 624 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 32 | Greenstreet YvonneDirector, Chief Executive Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $116K 316 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 32 | McBee BranninChief Development Officer | CRWVCoreWeave, Inc. Open-market sale · 10b5-1 plan | SELL | $646K 7,255 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 32 | McBee BranninChief Development Officer | CRWVCoreWeave, Inc. Open-market sale · 10b5-1 plan | SELL | $646K 7,254 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 32 | Greenstreet YvonneDirector, Chief Executive Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $215K 584 sh | Jan 14, 2026 traded Jan 12, 2026 |
| 32 | Greenstreet YvonneDirector, Chief Executive Officer | ALNYALNYLAM PHARMACEUTICALS, INC. Open-market sale | SELL | $96K 261 sh | Jan 14, 2026 traded Jan 12, 2026 |